Literature DB >> 8099803

Receptor occupancy in lumbar CSF as a measure of the antagonist activity of atenolol, metoprolol and propranolol in the CNS.

T Kaila1, R Marttila.   

Abstract

1. The antagonist activity of atenolol, metoprolol and propranolol in the CNS was estimated by determining the extent to which the drugs occupy animal beta 1- and beta 2-receptors in CSF ex vivo at the time of lumbar puncture. 2. Five CSF and plasma samples were obtained 4 h after drug intake from subjects treated for hypertension with atenolol, 100 mg once daily and five from subjects treated with metoprolol, 50 mg three times daily. Twenty-four samples were obtained 1, 2, 4 or 12 h after drug intake from subjects receiving a single 40 mg dose of propranolol. 3. The receptor occupancy in the samples was determined by adding beta 1-receptors of rabbit lung and beta 2-receptors of rat reticulocytes into the samples and labeling the receptors with a nonselective beta-adrenoceptor antagonist, (-)-[3H]-CGP-12177. 4. Atenolol and metoprolol occupied, as expected, larger fractions of beta 1- than beta 2-receptors in CSF and plasma samples. The receptor fraction occupied by atenolol in CSF was significantly (P < 0.05) lower than that occupied by metoprolol. The differences in occupancy between the drugs in plasma, however, were not statistically significant. 5. Propranolol occupied larger fractions of beta 2- than beta 1-receptors in the samples. Although propranolol concentrations in CSF were only 1/20-1/40 of those in plasma, the receptor occupancy of propranolol in CSF was similar to that in plasma.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099803      PMCID: PMC1381689          DOI: 10.1111/j.1365-2125.1993.tb04177.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Atenolol in hypertension a study of long-term therapy.

Authors:  F J Zacharias; K J Cowen; P F Cuthbertson; T B Johnson; J Prestt; J Thompson; J Vickers; W T Simpson; R Tuson
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

3.  Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4. Adverse effects. Choosing a beta-adrenoreceptor blocker.

Authors:  W Frishman; R Silverman; J Strom; U Elkayam; E Sonnenblick
Journal:  Am Heart J       Date:  1979-08       Impact factor: 4.749

4.  Nature and incidence of unwanted effects with atenolol.

Authors:  W T Simpson
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

5.  Evidence that ICI 118, 551 is a potent, highly Beta 2-selective adrenoceptor antagonist and can be used to characterize Beta-adrenoceptor populations in tissues.

Authors:  S R O'Donnell; J C Wanstall
Journal:  Life Sci       Date:  1980-08-25       Impact factor: 5.037

6.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

7.  A radioreceptor assay for propranolol and 4-hydroxypropranolol.

Authors:  C L Rochester; D E Gammon; E Shane; J P Bilezikian
Journal:  Clin Pharmacol Ther       Date:  1980-07       Impact factor: 6.875

8.  beta-Adrenoreceptor-blocking agents and the blood-brain barrier.

Authors:  J M Cruickshank; G Neil-Dwyer; M M Cameron; J McAinsh
Journal:  Clin Sci (Lond)       Date:  1980-12       Impact factor: 6.124

9.  Beta-Adrenergic receptor interactions. Direct comparison of receptor interaction and biological activity.

Authors:  E M Brown; S A Fedak; C J Woodard; G D Aurbach
Journal:  J Biol Chem       Date:  1976-03-10       Impact factor: 5.157

10.  Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol.

Authors:  J D Fitzgerald; S R O'Donnell
Journal:  Br J Pharmacol       Date:  1971-09       Impact factor: 8.739

View more
  3 in total

1.  Response of nasal airway and heart rate variability to controlled nasal breathing.

Authors:  W-H Fan; J-H Ko; M-J Lee; G Xu; Guo-She Lee
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-10-27       Impact factor: 2.503

2.  Extent of beta 1- and beta 2-receptor occupancy in plasma assesses the antagonist activity of metoprolol, pindolol, and propranolol in the elderly.

Authors:  T Kaila; E Iisalo; A Lehtonen; H Saarimaa
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

3.  Receptor binding assays in analysing the bioavailability and pharmacodynamic bioequivalence of active drug moieties. A study of metoprolol.

Authors:  T Kaila; L Roivas; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.